Open Access. Powered by Scholars. Published by Universities.®

Business Commons

Open Access. Powered by Scholars. Published by Universities.®

Articles 1 - 2 of 2

Full-Text Articles in Business

Estimating The Impact Of The Covid-19 Emergency On Tax Revenues In Guatemala: A Time Series Approach, Julio H. Cole Nov 2021

Estimating The Impact Of The Covid-19 Emergency On Tax Revenues In Guatemala: A Time Series Approach, Julio H. Cole

Journal of New Finance

Applications of time series models serve two different purposes: (1) as forecasting techniques, they are used to project the trajectory of a variable of interest during a certain number of future periods; (2) in the analysis of interventions, they are used to evaluate the effect of a significant disturbance on the process being studied. We use both types of application to study monthly tax revenues in Guatemala. In Section 2 we use data for 2010-2019 in order to compare two alternative models: (a) the Box-Jenkins (ARIMA) model, and (b) the Holt-Winters exponential smoothing model. In Section 3 we use post-2019 …


An Analysis Of Covid-19 Vaccine Allergic Reactions, Robert Schumaker, Michael Veronin, Trevor Rohm, Rohit Dixit, Shadi Aljawarneh, Juan Lara Jan 2021

An Analysis Of Covid-19 Vaccine Allergic Reactions, Robert Schumaker, Michael Veronin, Trevor Rohm, Rohit Dixit, Shadi Aljawarneh, Juan Lara

Journal of International Technology and Information Management

From our study, all three covid-19 vaccines have a similar proportion of adverse reaction reports in which the patient had a history of allergies. However, the proportion of life-threatening outcomes were lower for those with the Janssen vaccine (0.62% hospitalization rate for Janssen versus 2.59% for Pfizer and 0.60% death for Janssen versus 5.15% for Moderna). In terms of specific allergies, patients with *cillin or sulfa allergies had the most adverse reactions to covid-19 vaccines, however, Janssen again had the lowest percentage of reported deaths (1.39% for *cillin-related allergy deaths for Janssen versus 6.10% for Pfizer). In terms of patient …